{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:09:14Z","timestamp":1792807754854,"version":"4.5.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,12,21]]},"DOI":"10.1001\/jama.2021.21316","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T11:04:53Z","timestamp":1640084693000},"page":"2375","source":"Crossref","is-referenced-by-count":170,"title":["Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases"],"prefix":"10.1001","volume":"326","author":[{"given":"Silje Watterdal","family":"Syversen","sequence":"first","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin Kaasen","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akershus University Hospital, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guro L\u00f8vik","family":"Goll","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marthe Kirkes\u00e6ther","family":"Brun","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Sandanger","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin Hammersb\u00f8en","family":"Bj\u00f8rlykke","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sexton","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Christoffer","family":"Olsen","sequence":"additional","affiliation":[{"name":"Department of Research Support for Clinical Trials, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna Elin","family":"Gehin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"},{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David John","family":"Warren","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf Anton","family":"Klaasen","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geir","family":"Noraberg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hospital of Southern Norway Trust, Arendal, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trude Jannecke","family":"Bruun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The University Hospital of North Norway, Troms\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Kvikne","family":"Dotterud","sequence":"additional","affiliation":[{"name":"Department of Dermatology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud Kristine Aga","family":"Ljos\u00e5","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u00c5lesund Hospital, \u00c5lesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Julsrud","family":"Haugen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, \u00d8stfold Hospital Trust, Moss, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune Johan","family":"Nj\u00e5lla","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Nordland Hospital Trust, Bod\u00f8, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Zettel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Betanien Hospital, Skien, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl Magnus","family":"Ystr\u00f8m","sequence":"additional","affiliation":[{"name":"Department of Medicine, Innlandet Hospital Trust, Elverum, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngvill Hovde","family":"Bragnes","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Vestre Viken Hospital Trust, Drammen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svanaug","family":"Skorpe","sequence":"additional","affiliation":[{"name":"Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turid","family":"Thune","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine Aglen","family":"Seeberg","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Vestfold Hospital Trust, T\u00f8nsberg, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Michelsen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid Marianne","family":"Blomgren","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fonna Hospital Trust, Haugesund, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eldri Kveine","family":"Strand","sequence":"additional","affiliation":[{"name":"Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Mielnik","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rheumatology, and Physical Medicine, F\u00f8rde Hospital Trust, F\u00f8rde, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roald","family":"Torp","sequence":"additional","affiliation":[{"name":"Department of Medicine, Innlandet Hospital Trust, Hamar, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cato","family":"M\u00f8rk","sequence":"additional","affiliation":[{"name":"Akershus Dermatology Center, L\u00f8renskog, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore K.","family":"Kvien","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Jahnsen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Akershus University Hospital, L\u00f8renskog, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Bolstad","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A.","family":"Haavardsholm","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"joi210131r1","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition, epidemiology, and management.","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"joi210131r2","article-title":"Biologic drug survival in psoriasis: a systematic review and comparative meta-analysis.","volume":"7","author":"Mourad","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"joi210131r3","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.semarthrit.2020.06.020","article-title":"Discontinuation of biologic therapy due to lack\/loss of response and adverse events is similar between TNFi and non-TNFi class: results from a real-world rheumatoid arthritis cohort.","volume":"50","author":"Movahedi","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"joi210131r4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/rheumatology\/ket416","article-title":"It\u2019s like a juggling act: rheumatoid arthritis patient perspectives on daily life and flare while on current treatment regimes.","volume":"53","author":"Flurey","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"joi210131r5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13075-015-0730-2","article-title":"Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BEST study.","volume":"17","author":"Markusse","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"joi210131r6","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The role of early biologic therapy in inflammatory bowel disease.","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"joi210131r7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","article-title":"Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.","volume":"147","author":"Adedokun","year":"2014","journal-title":"Gastroenterology"},{"issue":"10","key":"joi210131r8","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn\u2019s disease.","volume":"64","author":"Vande Casteele","year":"2015","journal-title":"Gut"},{"issue":"6","key":"joi210131r9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/(ISSN)1529-0131","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"15","key":"joi210131r10","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1001\/jamainternmed.2013.7430","article-title":"Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis.","volume":"173","author":"Maneiro","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"9","key":"joi210131r11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases.","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"joi210131r12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment.","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"6","key":"joi210131r13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"joi210131r14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13063-019-3734-4","article-title":"Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study).","volume":"21","author":"Syversen","year":"2020","journal-title":"Trials"},{"issue":"17","key":"joi210131r15","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial.","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA"},{"issue":"20","key":"joi210131r16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"10086","key":"joi210131r17","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"joi210131r18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.v38:1","article-title":"Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"12","key":"joi210131r19","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/acr.v71.12","article-title":"2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures.","volume":"71","author":"England","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"joi210131r20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.","volume":"68","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"joi210131r21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores.","volume":"70","author":"Machado","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"joi210131r22","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"8167","key":"joi210131r23","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity.","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"issue":"4","key":"joi210131r24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohn\u2019s disease activity and Harvey-Bradshaw indices in assessing Crohn\u2019s disease severity.","volume":"8","author":"Vermeire","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"joi210131r25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid.","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"issue":"5","key":"joi210131r26","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD.","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"joi210131r27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cgh.2015.11.014","article-title":"Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis.","volume":"14","author":"Papamichael","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"joi210131r28","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"joi210131r29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/hesr.2009.44.issue-1","article-title":"What\u2019s the risk? a simple approach for estimating adjusted risk measures from nonlinear models including logistic regression.","volume":"44","author":"Kleinman","year":"2009","journal-title":"Health Serv Res"},{"issue":"2","key":"joi210131r30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/ibd\/izz131","article-title":"Proactive infliximab drug monitoring is superior to conventional management in inflammatory bowel disease.","volume":"26","author":"Fernandes","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"joi210131r31","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","article-title":"Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab.","volume":"15","author":"Papamichael","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"joi210131r32","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/j.gastro.2018.01.004","article-title":"Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients with active luminal Crohn\u2019s disease.","volume":"154","author":"D\u2019Haens","year":"2018","journal-title":"Gastroenterology"},{"issue":"17","key":"joi210131r33","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1001\/jama.2021.2740","article-title":"Treatment strategies for patients with immune-mediated inflammatory diseases.","volume":"325","author":"Curtis","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"joi210131r34","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease.","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"joi210131r35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus.","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"joi210131r36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/bjd.2006.155.issue-4","article-title":"A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician\u2019s Global Assessment and Lattice System Physician\u2019s Global Assessment.","volume":"155","author":"Berth-Jones","year":"2006","journal-title":"Br J Dermatol"},{"issue":"2","key":"joi210131r37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.","volume":"132","author":"D\u2019Haens","year":"2007","journal-title":"Gastroenterology"},{"key":"joi210131r38","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"issue":"11-12","key":"joi210131r39","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"joi210131r40","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3109\/s10165-009-0195-8","article-title":"Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING Study.","volume":"19","author":"Takeuchi","year":"2009","journal-title":"Mod Rheumatol"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2787318\/jama_syversen_2021_oi_210131_1640024195.79625.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T11:05:00Z","timestamp":1640084700000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2787318"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":40,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2021,12,21]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.21316","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12,21]]}}}